Workflow
Equus Total Return(EQS)
icon
Search documents
Equasens: Appointment at the head of the Pharmagest Division
Globenewswire· 2025-07-03 16:00
Villers-lès-Nancy (France), July 03, 2025 – 06 :00pm (CET) Press Release Equasens announces the departure of Damien VALICON, as Deputy Chief Executive Officer and Director of the Pharmagest Division He will be replaced by François-Pierre MARQUIER as Director of the Pharmagest Division. *** Equasens Group (Euronext Paris™ - Compartment B - FR 0012882389 –$EQS), announces the departure of Damien VALICON, who held the position of Deputy Chief Executive Officer and Director of the Pharmagest Division for 18 mo ...
Equasens: General meeting - Results of the votes
Globenewswire· 2025-07-01 17:00
Villers-lès-Nancy, 1st July 2025 – 07:00 p.m. (CET) PRESS RELEASE RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2025 Number of shares comprising the share capital: 15,174,125 Number of shares with voting rights: 14,830,415 Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,173,125 That means a quorum of 88.83% of the 14,830,415 shares with voting rights: the Ordinary Annual General Me ...
Equasens: acquisition of DIS and RESURGENCES BUSINESSES
Globenewswire· 2025-06-30 16:00
Core Viewpoint - Equasens Group has completed the acquisition of two businesses specializing in software solutions for the public healthcare sector, enhancing its position in the hospital and medico-social software market [3][4][10] Acquisition Details - The acquisition was finalized on July 1, 2025, through the AXIGATE LINK Division, covering over 300 customers in the public healthcare sector and generating annual sales of approximately €5 million [3][5][7] - The acquired businesses include the ResUrgences software platform, which manages hospital emergency services, and the DIS range, which provides digital solutions for public healthcare establishments [8][10] Strategic Goals - This acquisition aligns with Equasens' strategy to develop software solutions for public health establishments, capitalizing on numerous renewal and equipment opportunities in the market [6][10] - The integration aims to create a comprehensive technology ecosystem to support the digital transformation of both public and private healthcare establishments [4][10] Product and Service Expansion - The AXIGATE LINK Division will enhance its HOSPILINK solution for hospitals and specialized facilities, optimizing resources and accelerating innovation through technical and commercial synergies [5][9][10] - The short-term objective includes integrating new functionalities from the acquisition into existing product ranges, while the medium-term goal focuses on improving interoperability across various healthcare services [12][13] Leadership Commentary - The CEO of Equasens emphasized the acquisition's role in expanding and diversifying the company's core business, aiming to meet the growing digital needs of healthcare establishments [14] - The Deputy CEO highlighted the acquisition's significance in strengthening the company's presence in the public health sector, enhancing market share, expertise, and product range [14] Integration Timeline - Operational integration of the teams and solutions is set to begin in Q3 2025, with a phased migration plan for customers to Equasens' new technology platforms [15]
Equasens: availability of AGM preparatory materials
Globenewswire· 2025-06-06 16:00
Core Points - Equasens Group will hold its Annual Ordinary General Meeting on June 25, 2025, at 5:30 PM at its registered office in Villers-lès-Nancy [2] - The agenda and resolutions for the meeting were published in the French legal announcements on May 16, 2025 [3] - The Meeting Notice was published on June 6, 2025, detailing participation and voting procedures [4] Company Information - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,300 people across Europe [8] - The company provides specialized business applications that support healthcare professionals in various settings, including private practice and healthcare establishments [9] - Equasens Group focuses on interoperability solutions that enhance coordination among healthcare professionals, improving patient care and system efficiency [10] Meeting Logistics - The Annual General Meeting will be broadcast live online, with connection information available 48 hours prior to the meeting [7] - A replay of the meeting will also be accessible on the company's website for later viewing [7] - All relevant documents and voting forms are available on the company's website since June 4, 2025 [5]
Equus Receives Notice of Non-Compliance with New York Stock Exchange Share Price Rule
Globenewswire· 2025-05-20 21:15
Core Viewpoint - Equus Total Return, Inc. has been notified by the NYSE of non-compliance with listing standards due to its Common Stock trading below $1.00 for a consecutive 30-day period, but this notice does not affect its current listing or trading status [1][4]. Group 1: Compliance Notification - The NYSE notified Equus on May 15, 2025, regarding the non-compliance with Section 802.01C of the NYSE Listed Company Manual [1]. - The notice is classified as a deficiency notice and does not imply immediate delisting [1][4]. Group 2: Plans for Compliance - The Company plans to inform the NYSE by May 25, 2025, of its intention to remedy the stock price deficiency and return to compliance [2]. - Equus can regain compliance within six months if it achieves a closing share price of at least $1.00 on the last trading day of any calendar month during the cure period [2]. Group 3: Potential Actions for Compliance - The Company is considering various alternatives to address the stock price non-compliance, including a reverse stock split, which will be proposed at the upcoming annual meeting on June 26, 2025 [3]. - If the Company takes action requiring stockholder approval, the price condition will be deemed cured if the stock price exceeds $1.00 and remains above that level for at least 30 trading days [3]. Group 4: Ongoing Operations - Equus's Common Stock will continue to be listed and traded on the NYSE during the compliance period, provided it meets other listing standards [4]. - The notice is not expected to impact the Company's ongoing business operations or its reporting obligations with the U.S. Securities and Exchange Commission [4]. Group 5: Company Overview - Equus Total Return, Inc. operates as a business development company and trades as a closed-end fund on the NYSE under the symbol "EQS" [5].
Equus Total Return(EQS) - 2025 Q1 - Quarterly Report
2025-05-19 20:04
Financial Performance - Equus Total Return, Inc. aims to provide the highest total return through capital appreciation and current income [146]. - Net asset value increased from $2.17 per share to $2.52 per share, an increase of 16.0% [165]. - The Fund recorded a net investment loss of $1.1 million for the three months ended March 31, 2025 [174]. - The Fund purchased a senior convertible promissory note from General Enterprise Ventures for $1.5 million, with an increase of $3.0 million in fair value recorded [177]. - The Fund sold Equus Energy for $1.25 million in cash and 27,500 shares of preferred stock [178]. - The Fund recorded a reversal of unrealized depreciation of $4.1 million for its investment in Equus Energy, LLC [179]. - The Fund's common stock is trading at a 59.9% discount to its net asset value as of March 31, 2025 [165]. Economic Indicators - U.S. GDP contracted at an annualized rate of 0.3% in Q1 2025, following a 2.4% increase in Q4 2024, indicating economic challenges [159]. - The unemployment rate remained steady at 4.2% in April 2025, with the Congressional Budget Office predicting a slight increase to 4.5% for the remainder of 2025 [160]. - As of March 2025, the consumer price index increased by 2.4% over the previous 12 months, down from 2.8% in February 2025 [161]. - The introduction of tariffs in Q1 2025 is expected to increase inflation rates throughout the remainder of 2025 and into 2026 [161]. Interest Rates and Monetary Policy - The Federal Reserve cut interest rates by 50 basis points on September 18, 2024, marking the first reduction in four years [162]. Company Strategy and Operations - Equus plans to transform into an operating company, pending shareholder authorization expected in 2025 [153]. - The company has reduced its asset coverage ratio from 200% to 150%, allowing it to borrow up to twice the value of its net assets [154]. - The company has not incurred additional borrowings beyond a margin loan for U.S. Treasury bills since the asset coverage ratio reduction [154]. - The Fund's management has internalized management to achieve efficiencies in its cost structure as it grows [166]. Market Activity - Global merger and acquisition activity in 2024 was approximately $2.2 trillion, a slight increase from $2.1 trillion in 2023 [163]. - Private equity activity decreased from $464 billion in Q4 2024 to $445 billion in Q1 2025, with the U.S. accounting for roughly half of these totals [164]. - Analysts expect overall annual private equity activity to increase by 1.0% in 2025 over 2024, still 13.0% below the 2018-2019 average [164]. Capital Expenditures - In 2024, Morgan E&P, LLC incurred $6.4 million in capital expenditures for oil and gas development, with additional expenditures expected in 2025 [158].
Equasens: Q1 revenue at 31 March 2025
Globenewswire· 2025-05-12 16:00
Core Viewpoint - Equasens Group reported a revenue of €57.0 million for Q1 2025, reflecting a growth of 6.9% on a reported basis and 5.9% like-for-like compared to Q1 2024 [3][4]. Revenue Breakdown - The Pharmagest Division generated €42.0 million in revenue, marking a 5.5% increase on a reported basis [6][7]. - The Axigate Link Division reported revenue of €8.3 million, also up 5.5% on both reported and like-for-like bases [10][8]. - The e-Connect Division saw significant growth, with revenue reaching €3.5 million, up 21.2% on a reported and like-for-like basis [10][9]. - The Medical Solutions Division reported revenue of €2.7 million, a 25.1% increase on a reported basis, driven by the integration of CALIMED [10][11]. - The Fintech Division experienced a decline in revenue to €0.6 million, down 8.3% on both reported and like-for-like bases due to a restructuring of the customer base [21]. Business Type Performance - Sales of configurations and hardware increased by 7.7%, with Pharmagest and e-Connect showing strong growth [6][10]. - Scalable maintenance and professional training services grew by 3.5%, indicating customer loyalty [6][10]. - Software solutions and subscriptions rose by 11.3%, supported by acquisitions and organic growth [6][10]. Market Insights - The French market showed positive signals, with all business lines reporting growth, particularly in equipment sales [10]. - The Nursing Home sector benefited from public funding, while the Homecare sector maintained a promising level of new business [10]. - Revenue growth was also observed in Italy (up 13.3%), Belgium (up 4.8%), and Germany (up 12.5%) [10]. Future Outlook - The company is optimistic about growth in Q2 2025, supported by a strong order level in the Pharmacy sector [13]. - Equasens Group remains focused on external growth opportunities in France and Europe to strengthen its position in digital healthcare solutions [14].
Equasens: EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR
Globenewswire· 2025-04-30 06:00
Core Viewpoint - Equasens Group has initiated exclusive negotiations to acquire two software businesses in the public healthcare sector, aiming to enhance its market position and expand its solution offerings [3][6][11]. Group 1: Proposed Acquisition Details - The acquisition involves two complementary businesses: ResUrgences, a web-based platform for managing hospital emergency services, and the DIS suite of digital solutions for public healthcare establishments [4][5]. - If completed, these businesses will be integrated into the Axigate Link Division, which specializes in software for health and medico-social establishments [5]. Group 2: Strategic Focus - This acquisition aligns with Equasens' strategy to strengthen its market share in the rapidly growing public health software sector [6]. - The Group aims to enhance its portfolio with high value-added solutions, leveraging synergies with existing offerings to drive growth and innovation [7]. Group 3: Impact on Digital Transformation - The potential acquisition is expected to solidify Equasens' role in the digital transformation of the healthcare system by providing tailored solutions for healthcare establishments [8]. - The transaction is anticipated to be completed before the end of Q3 2025, subject to standard regulatory and employee consultation processes [9].
Equus Total Return(EQS) - 2024 Q4 - Annual Report
2025-04-10 20:01
Financing Activities - In Q1 2025, the company issued a 1-year senior convertible promissory note for $2.0 million at a 10.0% interest rate, convertible at $1.50 per share [16]. - The company purchased a senior convertible promissory note from General Enterprise Ventures, Inc. for $1.5 million, also at a 10% interest rate, convertible at $0.40 per share [16]. Investment Transactions - The sale of Equus Energy to North American Energy Opportunities Corp. was completed for $1.25 million in cash and 27,500 shares of preferred stock, potentially valued at $2.75 million [17]. Market Conditions - As of December 31, 2024, WTI oil prices were at $72.44, while natural gas prices stabilized at $3.40 per MMBTU [17]. Management Strategy - The company plans to pursue a more active management role in its investments to enhance shareholder value, including monitoring portfolio performance and exploring liquidity events [19]. - The investment strategy focuses on maximizing returns through debt and equity securities of small to middle market companies, with an emphasis on cash-producing investments [20]. - The company aims to maintain a substantial target market with favorable growth potential and strong competitive positions [25]. - Management seeks to invest in companies with experienced teams and significant management ownership to align interests and maximize shareholder value [24]. - The company is evaluating opportunities to transform into an operating company or permanent capital vehicle, pending stockholder approval [18]. Valuation and Investment Approach - The fair value of investments is determined based on portfolio company earnings, cash flow, and net worth, with adjustments reflecting market prices for similar securities and future financial prospects [38]. - The company intends to hold loans to maturity for privately held debt investments, believing that fair value will not exceed the cost of the investment [39]. - The company may engage independent third-party valuation firms to conduct appraisals and review preliminary valuations of privately-held investments [40]. Regulatory and Tax Considerations - The company has ceased to qualify as a regulated investment company (RIC) and may be taxed at regular corporate rates moving forward [14]. - The company has historically operated to qualify as a Regulated Investment Company (RIC) but elected not to qualify during Q4 2024, which subjects it to regular corporate tax rates [55]. - If the company requalifies as a RIC and distributes at least 90% of its taxable income, it will not be subject to federal income tax on distributed taxable income and capital gains [56]. - The company must meet specific diversification requirements to maintain RIC status, including having at least 50% of assets in cash and government securities [57]. - The company has the right to sell common stock below net asset value only with stockholder approval, including a majority of nonaffiliated stockholders [52]. - The company has no redemption rights for stockholders, and it may repurchase shares to reduce market value discounts [53]. - The company is subject to a 4.0% nondeductible federal excise tax if it does not distribute at least 98.2% of its net income consisting of capital gains within a one-year period [58]. Risks and Challenges - The company faces risks from economic conditions, including the impact of the coronavirus, which may negatively affect financial resources [64]. - The company depends on external financing for growth, which may be affected by borrowing arrangements and asset coverage requirements [64]. - The company is exposed to risks related to the default of portfolio companies on loans, which could impact operating results [64]. - The company cautions against undue reliance on forward-looking statements due to various uncertainties and risks [64]. Portfolio Composition - A significant portion of the investment portfolio consists of equity investments in private companies, with modest changes in public market equity prices generally not significantly impacting their estimated fair value [211]. - As of December 31, 2024, the "Energy" segment represents 93.1% of the company's net asset value and 91.9% of total assets [212]. - The company is classified as a "non-diversified" investment company, allowing it to invest a larger proportion of assets in a single user, which increases exposure to individual portfolio company performance [212]. Financial Instruments and Market Risks - The company does not use derivative financial instruments to mitigate financial market risks, including interest rate changes and foreign currency fluctuations [209]. - Changes in interest rates do not directly affect interest income from fixed-rate debt securities, as these are generally held to maturity [210]. - A hypothetical ten percent change in equity prices of publicly traded companies would result in a similar percentage change in the fair value of these securities [211].
Equasens: 2024 annual results
Globenewswire· 2025-03-28 17:00
Core Insights - The company reported a decline in key financial metrics for the year 2024, with revenue at €216.8 million, a decrease of 1.4% compared to 2023, and a net profit attributable to Group shareholders of €36.2 million, down 23.0% [2][4]. Financial Performance - Revenue for 2024 was €216.8 million, down from €219.7 million in 2023, reflecting a decrease of €3.0 million or 1.4% [2][4]. - Current Operating Income (COI) fell to €45.1 million, a decline of 19.2% from €55.8 million in 2023 [2][4]. - Net profit attributable to the Group decreased to €36.2 million, down €10.8 million or 23.0% from the previous year [2][4]. Division Analysis - **Pharmagest Division**: COI decreased to €30.7 million, down 16.4% from €36.7 million in 2023, primarily due to lower sales in the first half of the year [3][7]. - **Axigate Link Division**: Maintained a high profitability rate with COI at €10.2 million, a slight decrease of 2.3% from €10.4 million in 2023 [3][9]. - **e-Connect Division**: COI dropped to €4.8 million, down 28.0% from €6.7 million in 2023, attributed to lower sales [3][10]. - **Medical Solutions Division**: COI was €0.2 million, a significant decline of 92.0% from €2.2 million in 2023, as the division transitioned to new software solutions [3][12]. - **Fintech Division**: Experienced a deterioration in operating income, with COI at -€0.8 million, reflecting a significant decline of 73.4% in the second half of the year [3][14]. Strategic Outlook - The company aims for a return to revenue growth of close to 10% by the end of 2025, supported by investments in new solutions integrating artificial intelligence and cloud services [4][18]. - The strategy includes maintaining external growth initiatives in France and Europe while focusing on R&D and infrastructure investments [4][18]. Dividend Proposal - The Board of Directors proposed a gross dividend of €1.25 per share for fiscal 2024, to be discussed at the Annual General Meeting on June 25, 2025 [4][17]. Financial Health - The company reported a strong financial surplus of €79.5 million, indicating solid balance sheet structure despite the decline in profits [4][24].